Medable Inc., a leading provider of clinical development technology, today announced a collaboration with Google Cloud to bring Medable’s Digital and Decentralized Clinical Trial Platform to Google Cloud Marketplace. Customers will benefit from cutting-edge Google Cloud infrastructure and AI capabilities, seamlessly integrated with Medable’s platform, including the newly launched Studio, a unique SaaS solution that provides pharmaceutical companies control and transparency in clinical trial design, deployment, and management. Medable’s strategic collaboration with Google Cloud allows life sciences companies to accelerate clinical development while leveraging infrastructure and financial benefits.

Google Cloud Marketplace offers integrated solutions vetted by Google Cloud to support customers’ enterprise IT needs. Customers rely on Google Cloud Marketplace to identify and purchase the third-party tools that help them move to, build on, and work in Google Cloud. In addition to easier access, customers who purchase Medable solutions through Google Cloud Marketplace will benefit from consolidated billing and streamlined procurement. Medable usage will appear directly on Google Cloud invoices, and users will be able to pay for a portion of this usage with their committed Google Cloud spend.

“Bringing Medable’s platform to Google Cloud Marketplace will help customers quickly deploy, manage, and expand their use of the AI-driven clinical trial platform on Google Cloud's trusted, global infrastructure," said Dai Vu, managing director, Marketplace & ISV GTM Programs at Google Cloud.

Medable’s alliance with Google Cloud will benefit clinical trial sponsors by leveraging AI and advanced cloud technologies to accelerate trial design, execution, and data management. Further, customers can now take advantage of integrations across their enterprise and hybrid cloud environments while having easy access to Medable’s latest innovations.

“This alliance provides life sciences companies with Medable’s cutting-edge clinical development technology powered by Google Cloud through Google Cloud Marketplace,” said Dr. Michelle Longmire, co-founder and CEO of Medable. “The collaboration will enable scaled and seamless adoption of Medable solutions by Google Cloud users, providing life sciences companies with platform capabilities proven to improve patient access to trials and accelerate critical development efforts, globally.”

Medable, which ranked in the top 8% of software companies on the 2023 Inc. 5000, has deployed its software-as-a-service platform in more than 300 decentralized and hybrid clinical trials in 60 countries, serving more than one million patients and research participants globally. Customers have achieved impressive results – including 200 percent faster enrollment and 50 percent cost reductions. A Tufts CSDD study shows that, on average, decentralized trials can achieve net financial benefits from five to 13 times for Phase II and Phase III trials, equating to roughly $10 million ROI and $39 million ROI for an investment on average of $500K in Phase II and $1.5M in Phase III trials, respectively.

Learn more about the advantages of Medable’s collaboration with Google Cloud at Google Cloud’s inaugural Cancer AI Symposium, Wednesday, October 30, 2024, in Boston. Medable CEO and co-founder, Dr. Michelle Longmire, will be a featured speaker.

About Medable

Medable is on a mission to get effective therapies to people faster. Its digital clinical trials platform enhances speed, scale, and patient access in clinical research, accelerating medicines for thousands of conditions without treatment or cure. Awarded Best Digital Health Solution by the Galien Foundation, Medable’s platform has been deployed in nearly 400 trials in 70 countries and 120 languages, serving more than one million patients globally. Medable is a privately held, venture-backed company headquartered in Palo Alto, California, and was listed for the second year in a row on the Inc. 5000 in 2024.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241030519844/en/